Clinical Trial

Safety and Efficacy of FAP iCDC in Ischemic Cardiomyopathy

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety and efficacy of fibroblast activation protein (FAP)-targeted autologous immunosuppressive chimeric antigen receptor dendritic cell (iCDC) therapy in patients with ischemic cardiomyopathy, and to explore its potential as a novel therapeutic strategy for this disease.
Protocol Amendment History 4 changes
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
critical Recruitment opened 2026-07-03
notable Enrollment increased: 15 -> 30 participants 2026-07-03
minor Trial arms changed: 1 -> 2 2026-07-03
Trial Details
NCT Number NCT07505199
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Ischemic Cardiomyopathy, Cell Therapy
Enrollment 30 participants
Start Date 2026-05-21
Primary Completion 2028-04-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-02